Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
复制标题
口服促性腺激素释放激素拮抗剂用于治疗子宫平滑肌瘤。
DOI：
10.1097/aog.0000000000005145
复制
发表时间：
2023
影响因子：
7.2
通讯作者：
Stewart,ElizabethA
中科院分区：
文献类型：
--
作者：
Neblett2nd,MichaelF;Stewart,ElizabethA
财务披露 Elizabeth A. Stewart 报告称，AHRQ/PCORI 已向她的机构支付了 P50 HS023418 拨款，美国国立卫生研究院尤尼斯·肯尼迪·希弗儿童健康和人类发展研究所向她的机构支付了有关子宫腺肌病 CC 的 R01HD105714 拨款。她收到了拜耳的付款。她曾担任 AbbVie、ObsEva 和 Myovant 与子宫肌瘤和口服 GnRH 拮抗剂相关的顾问，但这些公司并不支持该项目。她拥有治疗异常子宫出血的方法和化合物的专利（US 6440445），该专利没有商业活动。她从 UpToDate 获得版税，并从 Med Learning Group、PER、马萨诸塞州医学会和 Peer View 获得教育内容开发费用。她还担任纤维瘤基金会的无薪顾问。 Michael F. Neblett II 没有报告任何潜在的利益冲突。 Elizabeth A. Stewart 还报告说，本文讨论的 Linzagolix 是第三种正在开发的用于治疗子宫肌瘤的口服 GnRH 拮抗剂，因为尽管它在美国被标记为研究性药物，但已在欧盟批准使用。
Financial Disclosure Elizabeth A. Stewart reports money was paid to her institution from AHRQ/PCORI for grant P50 HS023418 and from Eunice Kennedy Shiver Institute of Child Health and Human Development, National Institutes of Health CC, for grant R01HD105714 regarding adenomyosis CC. She received payment from Bayer. She has served as consultant for AbbVie, ObsEva, and Myovant related to uterine fibroids and oral GnRH antagonists, but those companies did not support this project. She holds a patent for Methods and Compounds for Treatment of Abnormal Uterine Bleeding (US 6440445), which has no commercial activity. She has received royalties from UpToDate and payments for the development of educational content from the Med Learning Group, PER, Massachusetts Medical Society, and Peer View. She also serves as an unpaid advisor to the Fibroid Foundation. Michael F. Neblett II did not report any potential conflicts of interest. Elizabeth A. Stewart also reported that Linzagolix is discussed in this article as the third oral GnRH antagonist in development for the treatment of uterine leiomyomas, since it is approved for use in the EU despite being labeled as investigational in the United States.